Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Operations: 2019-2025

Historic Cash from Operations for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$29.7 million.

  • Allogene Therapeutics' Cash from Operations rose 32.70% to -$29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.3 million, marking a year-over-year increase of 27.13%. This contributed to the annual value of -$200.3 million for FY2024, which is 15.75% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Cash from Operations stood at -$29.7 million, which was up 23.94% from -$39.0 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Cash from Operations peaked at -$29.7 million during Q3 2025, and registered a low of -$68.2 million during Q1 2022.
  • In the last 3 years, Allogene Therapeutics' Cash from Operations had a median value of -$53.7 million in 2023 and averaged -$50.9 million.
  • Per our database at Business Quant, Allogene Therapeutics' Cash from Operations tumbled by 355.50% in 2021 and then skyrocketed by 38.62% in 2025.
  • Allogene Therapeutics' Cash from Operations (Quarterly) stood at -$45.4 million in 2021, then crashed by 36.67% to -$62.1 million in 2022, then rose by 13.51% to -$53.7 million in 2023, then soared by 31.67% to -$36.7 million in 2024, then skyrocketed by 32.70% to -$29.7 million in 2025.
  • Its last three reported values are -$29.7 million in Q3 2025, -$39.0 million for Q2 2025, and -$52.9 million during Q1 2025.